REMS Retigabine Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As part of a post-marketing commitment, GSK will conduct a survey of prescribers' and pharmacists' understanding of the risk of urinary retention with retigabine products. This is to address the effectiveness of the Risk Evaluation and Mitigation Strategy (REMS) as outlined in the REMS approved by the FDA on 10th June 2011. The objectives of this survey are to assess prescribers' and pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention potentially associated with retigabine use as evaluated by a survey instrument.

This is a cross-sectional study of approximately 200 physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months, and 200 pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months. The primary outcome of the survey is the proportion of physicians and pharmacists providing correct responses to a series of questions concerning the risk of urinary retention and the symptoms of acute urinary retention that may be associated with retigabine. The risks captured will be those described in the retigabine Dear Healthcare Provider (DHCP) letters, specifically risks of urinary retention.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

NCT01607346

Epilepsy

TERMINATED PHASE4

Risk of Urinary Retention With Retigabine

NCT01462656

Epilepsy

TERMINATED

An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy

NCT01682681

Epilepsy

COMPLETED

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

NCT01721317

Seizures

TERMINATED PHASE4

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596

Seizures

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

POTIGA is a trademark of Valeant Pharmaceuticals North America, used by GlaxoSmithKline under license.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Physicians

Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.

Survey Responses

Intervention Type OTHER

Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.

Pharmacists

Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.

Survey Responses

Intervention Type OTHER

Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Survey Responses

Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to read, speak, and understand English.
* Willing to take the online survey or have the survey administered via a telephone interview, including electronically signing a Confidentiality \& Consent agreement and completing all study protocol-specified procedures.
* Prescribed retigabine within the past 12 months (prescribing physicians)
* Filled a prescription for at least one AED within the previous three months (pharmacists).

Exclusion Criteria

* Physicians or pharmacists meeting any of the following criteria will not be eligible to take the survey:
* The physician or pharmacist is currently employed by, or is a representative of any of the following:
* A pharmaceutical company or manufacturer of medicines or healthcare products.
* Contributor/editor to published guideline committees for epilepsy or UR.
* The physician or pharmacist has a visual impairment that would prevent him or her from being able to read independently.
* The physician or pharmacist participated in the Pilot REMS study for retigabine.
* The physician or pharmacist is an employee of GSK or Concentrics Research.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes